# US Alzheimers Disease Diagnostic Market > US Alzheimer's Disease Diagnostic Market Research Report: Size, Share, Trend Analysis By Types (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Tests (Genetic Testing, Neurological Exam, Mini Mental State Exam (MMSE), Brain Imaging, Others) and By End Users (Clinic, Hospital, Diagnostic Center, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.03% - **2024:** $ 2,800 Million - **2025:** $ 3,052.84 Million - **2035:** $ 7,250 Million - **Key Players:** Eli Lilly and Company (US), Biogen Inc. (US), Roche Holding AG (CH), Novartis AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), AbbVie Inc. (US) **Report ID:** MRFR/MED/14705-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** July 28, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-alzheimers-disease-diagnostic-market-16233 --- ## Market Summary ## **US Alzheimer's Disease Diagnostic Market Overview** As per MRFR analysis, the US Alzheimer's Disease Diagnostic Market Size was estimated at 1.1 (USD Billion) in 2024. The US Alzheimer's Disease Diagnostic Market Industry is expected to grow from 1.2(USD Billion) in 2025 to 2.78 (USD Billion) by 2035. The US Alzheimer's Disease Diagnostic Market CAGR (growth rate) is expected to be around 7.85% during the forecast period (2025 - 2035). ## **Key US Alzheimer's Disease Diagnostic Market Trends Highlighted** The US Alzheimer's Disease Diagnostic Market is experiencing significant trends driven by an increase in the aging population and a growing awareness of Alzheimer's disease. With millions of Americans aged 65 and older, a demographic that is particularly at risk for Alzheimer's, there is a heightened demand for accurate and early diagnostic tools. This shift is largely influenced by a push for better patient care, as early diagnosis can help in managing the disease more effectively. Additionally, advancements in technology, particularly in imaging techniques and biomarker testing, are transforming the diagnostic landscape. Tools that can detect Alzheimer’s even in its early stages are becoming more commonplace, improving the chances for timely intervention. Opportunities lie in the development of novel diagnostic methods and tests driven by ongoing research and clinical trials aimed at finding effective treatments or preventive measures for Alzheimer's. The involvement of various stakeholders, including academic institutions and biotech firms, presents a fertile ground for innovation within the US market. Recent trends also highlight the importance of integrating digital health technologies and artificial intelligence into diagnostic processes, allowing for more personalized and efficient patient management. As the healthcare system in the US shifts towards value-based care, the emphasis on quality diagnosis has never been more critical. Also, awareness campaigns from organizations such as the Alzheimer’s Association emphasize the importance of early diagnosis, further driving market growth. In this dynamic environment, stakeholders must navigate regulatory pathways while also addressing the needs of patients and caregivers in a rapidly evolving market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Alzheimer's Disease Diagnostic Market Drivers** Increasing Prevalence of Alzheimer's Disease The US Alzheimer's Disease Diagnostic Market is primarily driven by the increasing prevalence of Alzheimer's disease among the aging population in the United States. According to the Alzheimer’s Association data, approximately 6.5 million Americans aged 65 and older are living with Alzheimer’s disease, and this number is expected to rise to nearly 13 million by 2050. This surge in cases highlights the urgent need for effective diagnostic tools within the US Alzheimer's Disease Diagnostic Market Industry. As the population ages, the healthcare sector must adapt to meet the rising demand for early diagnosis and intervention, thereby ensuring that healthcare facilities and organizations will continue to invest heavily in developing and deploying new diagnostic solutions. Enhanced funding, resources, and talent directed toward Alzheimer’s research from established organizations such as the National Institutes of Health (NIH) have also bolstered growth in the market. The NIH allocated over $3 billion specifically for Alzheimer's research in the last fiscal year, underlining the governmental support for tackling this issue head-on. Technological Advancements in Diagnostic Tools Emerging technologies in diagnostic tools also serve as a significant driver for the US Alzheimer's Disease Diagnostic Market. Innovations such as advanced imaging techniques and biomarker-based tests are enhancing the accuracy and efficiency of Alzheimer’s diagnosis. For instance, novel PET scans are increasingly utilized to detect amyloid plaques in the brains of patients, which serve as key indicators of Alzheimer's disease. The National Institute on Aging is collaborating with various technology companies to develop state-of-the-art blood tests that can identify early signs of Alzheimer's at lower costs. These advancements unlock new diagnostic possibilities, enable earlier interventions, and are important for the development of the US Alzheimer's Disease Diagnostic Market Industry. 0Government Initiatives and Funding Government initiatives and funding for Alzheimer’s research and treatment have catalyzed growth in the US Alzheimer's Disease Diagnostic Market. Policies such as the National Plan to Address Alzheimer's Disease aim to prevent and effectively treat the disease by 2025. The funding raised from both federal and state levels has increased significantly, with reports indicating over $3.3 billion allocated for Alzheimer ’s-related research and development in recent budgets. This financial backing has empowered numerous research institutions and companies to innovate and launch diagnostic tools, ultimately leading to growth in the US Alzheimer's Disease Diagnostic Market Industry. Furthermore, with government-backed policies pushing for early detection and integrated care, the demand for reliable diagnostic solutions continues to rise. ## **US Alzheimer's Disease Diagnostic Market Segment Insights** ### **Alzheimer's Disease Diagnostic Market Type Insights** The US Alzheimer's Disease Diagnostic Market is a crucial segment within the healthcare industry, characterized by its focus on various types of Alzheimer's conditions, which ultimately drives the demand for effective diagnostic tools and methodologies. The segmentation of the US Alzheimer's Disease Diagnostic Market showcases several important types, including Early Onset Alzheimer's, Late Onset Alzheimer's, Familial Alzheimer's Disease, and Others. Early Onset Alzheimer's, which manifests before the age of 65, is particularly noteworthy as it presents unique diagnostic challenges and is often less understood compared to more commonly recognized forms. This underlines the need for enhanced research and screening processes, making its diagnostic market segment essential to address the distinct characteristics and requirements of affected individuals. Late Onset Alzheimer's, occurring most frequently in older adults, represents the majority of Alzheimer's cases diagnosed in the US, leading to a stronger focus on developing targeted diagnostic tools for this demographic. This market segment is critical as it faces considerable challenges related to identification and timely intervention due to the progressive nature of the disease. Familial Alzheimer's Disease, involving a genetic component and often presenting in younger populations compared to other types, underscores the importance of recognizing inheritance patterns in diagnostics. This highlights the necessity for specialized genetic testing and comprehensive family history assessments, which can significantly influence the diagnostic journey. Additionally, the "Others" category encompasses a range of atypical or mixed dementias, further emphasizing the complexity of diagnosing Alzheimer's variants that do not fit neatly into traditional classifications. As the US population ages and awareness of Alzheimer's disease increases, the demand for precise diagnostics across these types is projected to grow. The segment focuses on addressing key market growth drivers, including advancements in technology, such as biomarker identification and imaging techniques, resulting in improved diagnostic accuracy. However, challenges remain within the market, such as the high costs of innovative diagnostics and the need for increased access to testing, especially in rural areas where healthcare resources may be limited. The expanding realm of Alzheimer's disease diagnostics presents significant opportunities for both healthcare providers and technology developers seeking to innovate and enhance diagnostic accuracy and patient outcomes across the diverse types of this debilitating disease. The US Alzheimer's Disease Diagnostic Market revenue reflects a direct correlation with improved awareness, education, and advancements in detection methods, bolstering industry growth prospects as stakeholders seek to better serve patients and their families. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Alzheimer's Disease Diagnostic Market Diagnostic Tests Insights** The Diagnostic Tests segment of the US Alzheimer's Disease Diagnostic Market plays a crucial role in the early detection and management of Alzheimer's disease, a condition affecting millions in the United States. This segment comprises various methodologies, including Genetic Testing, Neurological Exams, the Mini Mental State Exam (MMSE), Brain Imaging, and Others, each contributing uniquely to the overall diagnostic landscape. Genetic Testing is significant due to its ability to reveal hereditary risk factors, aiding in proactive health management. Neurological Exams evaluate cognitive function and neurological health, allowing for timely intervention. The Mini Mental State Exam, a widely used tool, assists in assessing cognitive decline and monitoring disease progression. Brain Imaging technologies, such as MRI and PET scans, provide critical insights into structural and functional brain changes associated with Alzheimer’s. This variety of diagnostic approaches ensures comprehensive evaluation and personalized treatment plans. The US Alzheimer's Disease Diagnostic Market revenue is experiencing growth driven by factors like an aging population and advancements in technology, prompting increased demand for accurate and efficient diagnostic tests. With ongoing Research and Development, opportunities for improving diagnostic accuracy and patient outcomes continue to evolve in this vital segment. ### **Alzheimer's Disease Diagnostic Market End User Insights** The US Alzheimer's Disease Diagnostic Market, with a focus on the End User segment, comprises various settings where diagnostic tests and services are conducted, significantly impacting overall market dynamics. Clinics play a crucial role by providing accessible care and early detection, making them a primary point of contact for patients. Hospitals contribute with advanced imaging technology and neurological specialists, addressing complex cases and offering comprehensive treatment plans. Diagnostic Centers serve as specialized hubs for various neuropsychological tests, enhancing the accuracy and speed of diagnoses, thus appealing to a growing demand for precise evaluation. Others, including home health services and telemedicine platforms, are gaining importance due to the increasing aging population and the requirement for remote monitoring and consultations. As the prevalence of Alzheimer's disease in the United States continues to rise, the demand for effective diagnostic solutions across these diverse settings is expected to grow, highlighting a significant opportunity for advances in technology and service delivery within the US Alzheimer's Disease Diagnostic Market. Enhanced understanding of the disease and rising healthcare awareness create a strong foundation for market growth, leading to more robust US Alzheimer's Disease Diagnostic Market statistics and segmentation insights. The integration of innovative approaches in these varied settings presents a promising landscape for targeted research and development initiatives. **US Alzheimer's Disease Diagnostic Market Key Players and Competitive Insights:** The US Alzheimer's Disease Diagnostic Market is an evolving landscape characterized by significant advancements in technology and increasing recognition of the disease's impact on public health. The rise in the aging population, coupled with higher awareness and more sophisticated diagnostic methodologies, has led to a competitive environment where numerous players strive to establish their presence. Companies in this sector are engaged in developing innovative tools and solutions, such as biomarkers, imaging techniques, and cost-effective assessment systems, aimed at improving early detection and diagnosis of Alzheimer's disease. This market is shaped not just by product offerings but also by investments in research and development, strategic collaborations, and regulatory approvals. As newer diagnostic methods emerge, competition intensifies, compelling companies to differentiate their technologies and leverage partnerships to enhance their market positioning. AbbVie has carved a niche in the US Alzheimer's Disease Diagnostic Market by focusing on the integration of advanced biomarker assays and diagnostic imaging solutions. The company leverages its strong research capabilities and extensive portfolio to introduce products that address the pressing needs of early Alzheimer's detection. AbbVie’s approach involves collaborating with research institutions and other stakeholders to drive innovation. Their well-established brand recognition and commitment to quality solutions enhance their competitive edge in a rapidly evolving market. The company's robust pipeline also indicates a forward-thinking strategy that aligns with long-term health trends, enabling them to remain at the forefront of Alzheimer's diagnostics in the United States. Merck stands as a key player in the US Alzheimer's Disease Diagnostic Market through its commitment to innovative research and comprehensive diagnostic tools. The company focuses on developing targeted therapies that are connected with advanced diagnostics for Alzheimer's disease, enabling better clinical outcomes. Merck's key products often encompass a blend of pharmacological treatments and diagnostic tests that are designed to work in synergy, offering holistic management options for patients. In recent years, Merck has engaged in strategic mergers and acquisitions tailored to enhance its diagnostic capabilities and expand its market presence in the US This strategy not only strengthens its product lineup but also facilitates access to cutting-edge technologies and expertise, reinforcing Merck's role as a leader in the competitive landscape of Alzheimer's disease diagnostics. **Key Companies in the US Alzheimer's Disease Diagnostic Market Include:** **US Alzheimer's Disease Diagnostic Market Industry Developments** The US Alzheimer's Disease Diagnostic Market has witnessed significant developments recently, with companies such as Biogen, AbbVie, and Eli Lilly and Company actively advancing their diagnostic capabilities. In September 2023, Biogen announced the successful completion of clinical trials for its latest biomarker tests that aim to improve early detection methods. Meanwhile, in October 2023, AbbVie reported advancements in their imaging techniques associated with Alzheimer’s diagnosis. On the corporate front, Roche and Invitae Corporation both announced collaborative efforts to enhance genetic testing for Alzheimer’s, promoting a broader understanding of the disease's genetic predisposition. Additionally, in June 2022, Acumen Pharmaceuticals revealed its plan to acquire Neurocrine Biosciences to broaden its pipeline in therapeutic diagnostic solutions for Alzheimer's, a move expected to enhance market competition. The market has seen a rise in valuation, attributed to increasing investments in Research and Development by major firms including Merck and Johnson and Johnson, enhancing existing diagnostic technologies. Public awareness campaigns have also emphasized the importance of early diagnosis, further driving demand within this niche. Over the past few years, developments in advanced imaging techniques and blood tests have also contributed significantly to diagnostic accuracy, shaping the future of Alzheimer's diagnostics in the US ## **Alzheimer'S Disease Diagnostic Market Segmentation Insights** ### **Alzheimer's Disease Diagnostic Market Type Outlook** ### **Alzheimer's Disease Diagnostic Market Diagnostic Tests Outlook** ### **Alzheimer's Disease Diagnostic Market End User Outlook** ## Market Drivers ### Growing Demand for Early Diagnosis The growing demand for early diagnosis of Alzheimer's disease is a significant driver for the alzheimers disease-diagnostic market. Early detection is crucial for effective management and treatment, as it allows for timely interventions that can improve patient outcomes. Surveys indicate that over 80% of healthcare professionals believe that early diagnosis can lead to better care strategies. This demand is pushing healthcare systems to adopt advanced diagnostic tools, including neuroimaging and biomarker tests. The market for these diagnostic solutions is expected to grow by approximately 12% annually as healthcare providers seek to meet the needs of patients and their families. This trend highlights the importance of developing reliable and accessible diagnostic methods. ### Aging Population and Increased Awareness The aging population in the US is a critical driver for the alzheimers disease-diagnostic market. As the baby boomer generation ages, the number of individuals at risk for Alzheimer's disease is increasing. This demographic shift is accompanied by heightened awareness of Alzheimer's and its impact on families and communities. Educational campaigns and advocacy efforts have contributed to a greater understanding of the disease, leading to increased demand for diagnostic services. It is estimated that by 2030, nearly 20% of the US population will be over 65 years old, further amplifying the need for effective diagnostic solutions. This growing awareness is likely to drive market growth as more individuals seek diagnosis and treatment options. ### Rising Prevalence of Alzheimer's Disease The increasing prevalence of Alzheimer's disease in the US is a primary driver for the alzheimers disease-diagnostic market. According to the Alzheimer's Association, approximately 6.7 million individuals aged 65 and older are living with Alzheimer's in the US as of 2025. This number is projected to rise significantly, potentially reaching 14 million by 2060. The growing patient population necessitates enhanced diagnostic tools and methods, thereby stimulating market growth. As awareness of the disease increases, healthcare providers are more inclined to adopt advanced diagnostic solutions, which could lead to a market expansion of around 10% annually. This trend underscores the urgent need for effective diagnostic strategies to manage the rising burden of Alzheimer's disease. ### Increased Funding for Alzheimer's Research In recent years, there has been a notable increase in funding for Alzheimer's research in the US, which serves as a crucial driver for the alzheimers disease-diagnostic market. The National Institutes of Health (NIH) allocated approximately $3.5 billion for Alzheimer's research in 2025, reflecting a commitment to understanding and diagnosing the disease. This financial support fosters innovation in diagnostic technologies, encouraging the development of novel biomarkers and imaging techniques. As research progresses, new diagnostic tools are likely to emerge, enhancing the accuracy and speed of Alzheimer's diagnosis. This influx of funding not only propels the market forward but also raises public awareness, potentially leading to earlier detection and intervention. ### Technological Innovations in Diagnostic Tools Technological innovations are transforming the landscape of the alzheimers disease-diagnostic market. Advancements in neuroimaging techniques, such as PET scans and MRI, have significantly improved the ability to detect Alzheimer's disease at earlier stages. Additionally, the development of blood-based biomarkers is emerging as a promising area of research, potentially offering less invasive and more cost-effective diagnostic options. The integration of these technologies into clinical practice is expected to enhance diagnostic accuracy and efficiency. As a result, the market is projected to experience a compound annual growth rate (CAGR) of around 11% over the next five years, driven by the continuous evolution of diagnostic tools and methodologies. ## Future Outlook The [Alzheimers Disease Diagnostic Market](https://www.marketresearchfuture.com/reports/alzheimers-disease-diagnostic-market-2149) is projected to grow at a 9.03% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and enhanced awareness. **New opportunities:** - Development of AI-driven diagnostic tools for early detection. - - Expansion of telehealth services for remote patient monitoring. - Partnerships with pharmaceutical companies for integrated diagnostic solutions. By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnostics and increased demand. ## Segment Insights ### By Type: Late Onset Alzheimers (Largest) vs. Early Onset Alzheimers (Fastest-Growing) The US alzheimers disease-diagnostic market is characterized by a diverse array of segment values. Among these segments, Late Onset Alzheimers holds the largest share, driven by the increasing aging population and a higher prevalence of age-related cognitive decline. Conversely, Early Onset Alzheimers is gaining attention as a rapidly growing segment, fueled by rising awareness and advancements in diagnostic methodologies. Growth trends in the market are largely influenced by research innovations and the healthcare infrastructure in place for the diagnosis of Alzheimer's. Factors such as increased funding for research, public awareness campaigns, and collaborations between healthcare organizations and diagnostic companies play crucial roles in driving growth in both Late and Early Onset Alzheimers segments, ensuring that more individuals receive timely diagnoses and appropriate care. Late Onset Alzheimers (Dominant) vs. Early Onset Alzheimers (Emerging) Late Onset Alzheimers is established as the dominant segment in the US alzheimers disease-diagnostic market, characterized by a higher incidence in older adults typically aged 65 and above. This segment benefits from robust diagnostic frameworks and strategies aimed at understanding the complexities of late-stage cognitive decline, which includes comprehensive neuropsychological testing and imaging technologies. On the other hand, Early Onset Alzheimers, often diagnosed in individuals as young as 30s or 40s, represents an emerging segment that is garnering increased attention due to the early onset of symptoms and the significant impact it has on the quality of life. The awareness surrounding early diagnosis is increasing, leading to advancements in diagnostic technologies specifically tailored for younger populations. ### By Diagnostic Tests: Genetic Testing (Largest) vs. Neurological Exam (Fastest-Growing) In the US alzheimers disease-diagnostic market, Genetic Testing holds the largest market share, signifying its pivotal role in early diagnosis and patient management. Neurological Exams, while gaining traction, serve as complementary tools, optimizing diagnostic accuracy. The diversification within these testing methodologies reflects the market's adaptive strategies to cater to evolving healthcare needs. The landscape is witnessing a significant shift as Neurological Exams exhibit rapid growth due to increasing awareness of Alzheimer’s symptoms and advancements in diagnostic technologies. Also, Genetic Testing continues to flourish amidst rising interest in personalized medicine. Factors such as an aging population and enhanced insurance coverage for diagnostic tests contribute to this positive momentum, enabling more patients to seek timely evaluations and results. Genetic Testing: Dominant vs. Neurological Exam: Emerging Genetic Testing proves to be the dominant force in the diagnostic process for Alzheimer's, offering insights into hereditary factors and risk assessments which are vital for at-risk populations. Its established methodology appeals to both clinicians and patients, providing a layer of reassurance through scientific validation. On the other hand, Neurological Exams emerge as an essential and growing segment, focusing on physical assessments and cognitive evaluations, which are pivotal in understanding the disease's progression. These exams are increasingly recognized for their role in comprehensive evaluations, thus attracting healthcare providers aiming for a holistic approach to patient care. This dichotomy highlights a rich spectrum of options available in the market, catering to diverse patient needs. ### By End User: Hospital (Largest) vs. Clinic (Fastest-Growing) In the US alzheimers disease-diagnostic market, hospitals account for the largest share among end users, largely due to their capacity to provide comprehensive diagnostic services, advanced technology, and immediate access to specialist care. Clinics, while smaller in market share, are gaining traction and are expected to see significant growth as they offer accessible and specialized services to patients. Hospital: (Dominant) vs. Clinic (Emerging) Hospitals hold a dominant position in this market, equipped with extensive resources and multidisciplinary teams that facilitate accurate diagnosis and treatment for Alzheimer's disease. They are often the first point of referral for patients showing symptoms, due to their large-scale operations and integrated healthcare models. On the other hand, clinics are emerging rapidly, driven by an increasing focus on outpatient services and personalized care. They often provide quicker and more convenient access to diagnostic services, catering to a growing patient preference for localized care options. This shift is indicative of a broader trend towards efficiency and specialization in Alzheimer's diagnostics. ## Competitive Benchmarking The [alzheimers disease-diagnostic market](https://www.marketresearchfuture.com/reports/alzheimers-disease-diagnostic-market-2149)is characterized by a dynamic competitive landscape, driven by the increasing prevalence of Alzheimer’s disease and the urgent need for effective diagnostic solutions. Key players such as Eli Lilly and Company (US), Biogen Inc. (US), and Roche Holding AG (CH) are at the forefront, each adopting distinct strategies to enhance their market positioning. Eli Lilly (US) focuses on innovation, particularly in developing novel biomarkers for early detection, while Biogen (US) emphasizes partnerships with academic institutions to advance research. Roche (CH) leverages its extensive diagnostic portfolio to integrate digital health solutions, thereby enhancing patient outcomes and operational efficiency. Collectively, these strategies contribute to a competitive environment that is increasingly centered on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure fosters an environment where innovation and strategic partnerships are critical for success, as companies seek to differentiate themselves in a crowded marketplace. In October Eli Lilly and Company (US) announced a collaboration with a leading tech firm to develop an AI-driven diagnostic tool aimed at improving early detection rates of Alzheimer’s disease. This strategic move is likely to enhance Eli Lilly’s competitive edge by integrating cutting-edge technology into its diagnostic offerings, potentially leading to more accurate and timely diagnoses. In September Biogen Inc. (US) launched a new clinical trial focused on a blood-based biomarker for Alzheimer’s detection, in partnership with a prominent research university. This initiative underscores Biogen’s commitment to advancing diagnostic capabilities and may position the company as a leader in the development of non-invasive testing methods, which are increasingly favored by both clinicians and patients. In August Roche Holding AG (CH) expanded its diagnostic services by acquiring a startup specializing in digital health solutions for Alzheimer’s care. This acquisition is indicative of Roche’s strategy to enhance its service offerings and integrate technology into its diagnostic processes, thereby improving patient management and outcomes. As of November current trends in the alzheimers disease-diagnostic market include a pronounced shift towards digitalization and AI integration, which are reshaping competitive dynamics. Strategic alliances are becoming increasingly vital, as companies recognize the need for collaborative approaches to tackle complex challenges in diagnosis and treatment. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than price-based competition. Companies that can reliably integrate advanced technologies into their diagnostic processes are likely to gain a significant advantage in this rapidly evolving market. ## Recent News & Developments The US Alzheimer's Disease Diagnostic Market has witnessed significant developments recently, with companies such as Biogen, AbbVie, and Eli Lilly and Company actively advancing their diagnostic capabilities. In September 2023, Biogen announced the successful completion of clinical trials for its latest biomarker tests that aim to improve early detection methods. Meanwhile, in October 2023, AbbVie reported advancements in their imaging techniques associated with Alzheimer’s diagnosis. On the corporate front, Roche and Invitae Corporation both announced collaborative efforts to enhance genetic testing for Alzheimer’s, promoting a broader understanding of the disease's genetic predisposition. Additionally, in June 2022, Acumen Pharmaceuticals revealed its plan to acquire Neurocrine Biosciences to broaden its pipeline in therapeutic diagnostic solutions for Alzheimer's, a move expected to enhance market competition. The market has seen a rise in valuation, attributed to increasing investments in Research and Development by major firms including Merck and Johnson and Johnson, enhancing existing diagnostic technologies. Public awareness campaigns have also emphasized the importance of early diagnosis, further driving demand within this niche. Over the past few years, developments in advanced imaging techniques and blood tests have also contributed significantly to diagnostic accuracy, shaping the future of Alzheimer's diagnostics in the US ## Report Scope | MARKET SIZE 2024 | 2800.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 3052.84(USD Million) | | MARKET SIZE 2035 | 7250.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.03% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Eli Lilly and Company (US), Biogen Inc. (US), Roche Holding AG (CH), Novartis AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Johnson & Johnson (US), AbbVie Inc. (US) | | Segments Covered | Type, Diagnostic Tests, End User | | Key Market Opportunities | Advancements in biomarker discovery enhance early detection capabilities in the alzheimers disease-diagnostic market. | | Key Market Dynamics | Technological advancements in biomarkers enhance diagnostic accuracy, driving competitive dynamics in the Alzheimer's disease-diagnostic market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US Alzheimer's disease-diagnostic market?** A: The market valuation was $2800.0 Million in 2024. **Q: What is the projected market size for the US Alzheimer's disease-diagnostic market by 2035?** A: The market is expected to reach $7250.0 Million by 2035. **Q: What is the expected CAGR for the US Alzheimer's disease-diagnostic market during the forecast period 2025 - 2035?** A: The expected CAGR is 9.03% during the forecast period. **Q: Which companies are the key players in the US Alzheimer's disease-diagnostic market?** A: Key players include Eli Lilly and Company, Biogen Inc., Roche Holding AG, Novartis AG, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson, and AbbVie Inc. **Q: What are the main segments of the US Alzheimer's disease-diagnostic market?** A: The main segments include Type, Diagnostic Tests, and End User. **Q: What was the market valuation for Early Onset Alzheimer's in 2024?** A: The market valuation for Early Onset Alzheimer's was $280.0 Million in 2024. **Q: How much is the Late Onset Alzheimer's segment projected to grow by 2035?** A: The Late Onset Alzheimer's segment is projected to grow to $2100.0 Million by 2035. **Q: What is the valuation range for Brain Imaging as a diagnostic test?** A: The valuation range for Brain Imaging is $1120.0 Million to $2800.0 Million. **Q: Which end user segment had a valuation of $840.0 Million in 2024?** A: The Hospital end user segment had a valuation of $840.0 Million in 2024. **Q: What is the projected valuation for Genetic Testing by 2035?** A: The projected valuation for Genetic Testing is expected to reach $725.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-alzheimers-disease-diagnostic-market-16233*